Ameritas Investment Partners’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Ameritas Investment Partners’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.5K	Hold	6,026	–	–	﹤0.01%	2627
2025 Q4	$21.5K	Hold	6,026	–	–	﹤0.01%	2609
2025 Q3	$21K	Hold	6,026	–	–	﹤0.01%	2634
2025 Q2	$12.4K	Buy	+6,026	New	+$15.1K	﹤0.01%	2895
2023 Q2	–	Sell	-1,409	Closed	-$955	–	3208
2023 Q1	$955	Hold	1,409	–	–	﹤0.01%	2983
2022 Q4	$2.03K	Hold	1,409	–	–	﹤0.01%	3011
2022 Q3	$6K	Hold	1,409	–	–	﹤0.01%	2904
2022 Q2	$7K	Buy	+1,409	New	+$10.3K	﹤0.01%	2918

Other funds holding STLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's STLN Position: Q1 2026 in Review

Ameritas Investment Partners held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q1 2026 at 6,026 shares worth $18.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2627.

Ameritas Investment Partners first reported a position in STLN in Q2 2022 and has held it in 8 quarters since. The position peaked at $21.5K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

Ameritas Investment Partners held 6,026 shares of Starling Oncology Institute, Inc. Common Stock worth $18.5K as of Q1 2026.
Ameritas Investment Partners left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q1 2026.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2627 holding.
Ameritas Investment Partners first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2022 and has held it in 8 quarters since.
Ameritas Investment Partners's Starling Oncology Institute, Inc. Common Stock position peaked at $21.5K in Q4 2025.
115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.